EBV‐directed viral‐specific T‐lymphocyte therapy for the treatment of EBV‐driven lymphoma in two patients with primary immunodeficiency and DNA repair defects
暂无分享,去创建一个
P. Hanley | M. Absalon | C. Lutzko | S. Davies | K. Burns | Jeremy D. Rubinstein | M. Grimley | A. Nelson | S. Chandra | M. Keller | T. Leemhuis
[1] A. Gennery,et al. Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working Group , 2018, Front. Immunol..
[2] H. Ea,et al. Spontaneous resolution of Epstein-Barr virus-induced haemophagocytic lymphohistiocytosis in Still’s disease treated by tocilizumab: a case report , 2018, Scandinavian journal of rheumatology.
[3] R. Hutchinson,et al. Ataxia Telangiectasia and Cancer Predisposition: Challenges in Management. , 2017, Journal of pediatric hematology/oncology.
[4] C. Bollard,et al. Virus-Specific T Cells for the Immunocompromised Patient , 2017, Front. Immunol..
[5] R. Krance,et al. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Plon,et al. Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders , 2017, Clinical Cancer Research.
[7] N. Mahlaoui,et al. Advances in the Care of Primary Immunodeficiencies (PIDs): from Birth to Adulthood , 2017, Journal of Clinical Immunology.
[8] A. Etzioni,et al. Ataxia-telangiectasia: Immunodeficiency and survival. , 2017, Clinical immunology.
[9] J. Minárovits,et al. Epstein Barr Virus , 2017, Methods in Molecular Biology.
[10] T. Crawford,et al. Ataxia telangiectasia: a review , 2016, Orphanet Journal of Rare Diseases.
[11] C. Houldcroft,et al. Severe Epstein–Barr virus infection in primary immunodeficiency and the normal host , 2016, British journal of haematology.
[12] H. Takada,et al. A nationwide survey of common viral infections in childhood among patients with primary immunodeficiency diseases. , 2016, The Journal of infection.
[13] W. Klapper,et al. High incidence of Epstein–Barr virus (EBV)‐positive Hodgkin lymphoma and Hodgkin lymphoma‐like B‐cell lymphoproliferations with EBV latency profile 2 in children with interleukin‐2‐inducible T‐cell kinase deficiency , 2015, Histopathology.
[14] Zhe Zhang,et al. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening , 2015, PloS one.
[15] T. Gasser,et al. Clinical variability in ataxia–telangiectasia , 2015, Journal of Neurology.
[16] M. Luftig,et al. To Be or Not IIb: A Multi-Step Process for Epstein-Barr Virus Latency Establishment and Consequences for B Cell Tumorigenesis , 2015, PLoS pathogens.
[17] A. Fischer,et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] A. Fischer,et al. Prevention of infections during primary immunodeficiency. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] Malcolm K. Brenner,et al. Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT , 2014, Science Translational Medicine.
[20] R. Krance,et al. Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] Y. Zu,et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Borkhardt,et al. Primary immunodeficiencies predisposed to Epstein‐Barr virus‐driven haematological diseases , 2013, British journal of haematology.
[23] U. Gerdemann,et al. Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections , 2012, Molecular Therapy.
[24] J. Teruya-Feldstein,et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. , 2012, Blood.
[25] P. Schlattmann,et al. IL‐6 and IL‐10 in post‐transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T‐cell subsets in 38 patients undergoing treatment , 2011, Transplant international : official journal of the European Society for Organ Transplantation.
[26] H. Heslop,et al. Immunotherapy targeting EBV-expressing lymphoproliferative diseases. , 2008, Best practice & research. Clinical haematology.
[27] H. Wacker,et al. Differentiation of EBV‐induced post‐transplant Hodgkin lymphoma from Hodgkin‐like post‐transplant lymphoproliferative disease , 2008, Pediatric transplantation.
[28] A. Swerdlow,et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. , 2007, Blood.
[29] T. Kanda,et al. Epstein-Barr Virus BZLF1 Gene, a Switch from Latency to Lytic Infection, Is Expressed as an Immediate-Early Gene after Primary Infection of B Lymphocytes , 2006, Journal of Virology.
[30] K. Lucas,et al. Adoptive immunotherapy with allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes for recurrent, EBV‐positive Hodgkin disease , 2004, Cancer.
[31] M. Swift,et al. Hodgkin disease in ataxia-telangiectasia patients with poor outcomes. , 2003, Medical and pediatric oncology.
[32] R. Tamminga,et al. CHEMO- AND RADIOSENSITIVITY TESTING IN A PATIENT WITH ATAXIA TELANGIECTASIA AND HODGKIN DISEASE , 2002, Pediatric hematology and oncology.
[33] Sara G. Becker-Catania,et al. Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. , 1999, American journal of human genetics.